Journal of advanced research · 2026
Genetic identification of the FcδR complex: TRβV12-4 as the IgD-binding domain targeted for immunotherapy in rheumatoid arthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Xiaoxi, Han Chenchen, Huang Dongliang, Xu Jing, He Jingjing, Wu Tiantian, Dong Manling, Zhao Jiemin, Li Tao, Wu Yujing, Wei Wei
Аннотация
INTRODUCTION: Rheumatoid arthritis (RA) is a chronic autoimmune disease that drives progressive joint destruction and functional disability. Current therapies are often limited by inadequate efficacy and risks of broad immunosuppression. Immunoglobulin D (IgD) is a conserved antibody isotype with poorly understood functions. We previously reported aberrant IgD secretion in RA and its capacity to activate T cells, yet the putative IgD receptor (FcδR) remained unidentified.
OBJECTIVES: To identify and characterize FcδR, elucidate the molecular mechanisms involved in T-cell activation, define its pathogenic role in RA, and evaluate its therapeutic potential as a new target.
METHODS: FcδR was identified by affinity pull-down using IgD-Fc as bait, followed by mass spectrometry analysis. Molecular interactions were further confirmed by molecular docking, surface plasmon resonance (SPR) analysis and co-immunoprecipitation. IgD-triggered signaling was analyzed using CRISPR/Cas9-engineered TRβV12-4 knockout and overexpression cells. Therapeutic blockade was evaluated using IgD-Fc-Ig as a competitive antagonist in vitro and in vivo using AAV-mediated FcδR-overexpressing collagen-induced arthritis (CIA) mouse model.
RESULTS: FcδR was identified as a heteromeric complex of TRβV12-4 with CD3ε/CD3ζ. IgD binding to TRβV12-4 activated T cells via CD3-mediated Lck-ZAP70 signaling. The IgD-Fc-Ig fusion protein competitively blocked IgD-FcδR interaction, suppressing pathological T-cell activation. In CIA mice, FcδR expression correlated with inflammatory severity, and FcδR blockade via IgD-Fc-Ig administration significantly attenuated arthritic progression.
CONCLUSION: This study identifies FcδR as a previously unrecognized IgD Fc receptor complex comprising TRβV12-4 and CD3ε/CD3ζ, triggering T-cell activation via IgD and driving RA pathogenesis. IgD-Fc-Ig competitively blocks IgD-FcδR and exerts therapeutic effects in CIA. These findings establish FcδR as a novel therapeutic target and a promising strategy for RA treatment.
OBJECTIVES: To identify and characterize FcδR, elucidate the molecular mechanisms involved in T-cell activation, define its pathogenic role in RA, and evaluate its therapeutic potential as a new target.
METHODS: FcδR was identified by affinity pull-down using IgD-Fc as bait, followed by mass spectrometry analysis. Molecular interactions were further confirmed by molecular docking, surface plasmon resonance (SPR) analysis and co-immunoprecipitation. IgD-triggered signaling was analyzed using CRISPR/Cas9-engineered TRβV12-4 knockout and overexpression cells. Therapeutic blockade was evaluated using IgD-Fc-Ig as a competitive antagonist in vitro and in vivo using AAV-mediated FcδR-overexpressing collagen-induced arthritis (CIA) mouse model.
RESULTS: FcδR was identified as a heteromeric complex of TRβV12-4 with CD3ε/CD3ζ. IgD binding to TRβV12-4 activated T cells via CD3-mediated Lck-ZAP70 signaling. The IgD-Fc-Ig fusion protein competitively blocked IgD-FcδR interaction, suppressing pathological T-cell activation. In CIA mice, FcδR expression correlated with inflammatory severity, and FcδR blockade via IgD-Fc-Ig administration significantly attenuated arthritic progression.
CONCLUSION: This study identifies FcδR as a previously unrecognized IgD Fc receptor complex comprising TRβV12-4 and CD3ε/CD3ζ, triggering T-cell activation via IgD and driving RA pathogenesis. IgD-Fc-Ig competitively blocks IgD-FcδR and exerts therapeutic effects in CIA. These findings establish FcδR as a novel therapeutic target and a promising strategy for RA treatment.